Outlook Therapeutics' wet AMD therapy ONS-5010 clinical trial did not meet the primary endpoint
I'm PortAI, I can summarize articles.
Outlook Therapeutics announced that its clinical trial for the wet age-related macular degeneration (AMD) therapy ONS-5010 did not meet its primary endpoint, causing the stock price to plummet about 82% in pre-market trading on Wednesday. Nevertheless, the company stated that ONS-5010 has biological activity and good safety, planning to resubmit its listing application in the first quarter of 2025, and expects to announce the three-month data analysis results in January next year
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments